Total Funding
21
31
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
105085
Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
- Shao-Lee Lin: EVP, Head of Research and DevelopmentPast Role: ACELYRIN, Founder and Chief Executive Officer
Ben Bove: Senior Vice President, Marketing & Commercial Analytics
About the Company
Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of
naproxen and famotidine.
Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.
